SBI Securities
KPTI icon

SBI Securities’s Karyopharm Therapeutics KPTI Stock Holding History

SBI Securities’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$84 Buy
69
+2
+3% +$8 ﹤0.01% 3626
2026
Q2 		$655 Hold
67
– – ﹤0.01% 2944
2026
Q1 		$373 Sell
67
-7
-9% -$53 ﹤0.01% 2998
2025
Q4 		$545 Hold
74
– – ﹤0.01% 2844
2025
Q3 		$484 Hold
74
– – ﹤0.01% 2982
2025
Q2 		$319 Hold
74
– – ﹤0.01% 3151
2025
Q1 		$277 Buy
74
+26
+54% +$222 ﹤0.01% 3103
2024
Q4 		$485 Buy
+48
New +$580 ﹤0.01% 2900

Other funds holding KPTI

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

SBI Securities's KPTI Position: Q3 2026 in Review

SBI Securities increased its Karyopharm Therapeutics (KPTI) stake by 3% in Q3 2026, buying an estimated $8 and bringing the position to 69 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #3626.

SBI Securities first reported a position in KPTI in Q4 2024 and has held it in 8 quarters since. The position peaked at $655 in Q2 2026. 39 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • SBI Securities held 69 shares of Karyopharm Therapeutics worth $84 as of Q3 2026.
  • SBI Securities bought 2 Karyopharm Therapeutics shares in Q3 2026, an estimated $8.
  • Karyopharm Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3626 holding.
  • SBI Securities first reported a position in Karyopharm Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Karyopharm Therapeutics position peaked at $655 in Q2 2026.
  • 39 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.